E-viri
Odprti dostop
-
Dobson, Stephanie M; García-Prat, Laura; Vanner, Robert J; Wintersinger, Jeffrey; Waanders, Esmé; Gu, Zhaohui; McLeod, Jessica; Gan, Olga I; Grandal, Ildiko; Payne-Turner, Debbie; Edmonson, Michael N; Ma, Xiaotu; Fan, Yiping; Voisin, Veronique; Chan-Seng-Yue, Michelle; Xie, Stephanie Z; Hosseini, Mohsen; Abelson, Sagi; Gupta, Pankaj; Rusch, Michael; Shao, Ying; Olsen, Scott R; Neale, Geoffrey; Chan, Steven M; Bader, Gary; Easton, John; Guidos, Cynthia J; Danska, Jayne S; Zhang, Jinghui; Minden, Mark D; Morris, Quaid; Mullighan, Charles G; Dick, John E
Cancer discovery, 04/2020, Letnik: 10, Številka: 4Journal Article
Disease recurrence causes significant mortality in B-progenitor acute lymphoblastic leukemia (B-ALL). Genomic analysis of matched diagnosis and relapse samples shows relapse often arising from minor diagnosis subclones. However, why therapy eradicates some subclones while others survive and progress to relapse remains obscure. Elucidation of mechanisms underlying these differing fates requires functional analysis of isolated subclones. Here, large-scale limiting dilution xenografting of diagnosis and relapse samples, combined with targeted sequencing, identified and isolated minor diagnosis subclones that initiate an evolutionary trajectory toward relapse termed diagnosis Relapse Initiating clones (dRI). Compared with other diagnosis subclones, dRIs were drug-tolerant with distinct engraftment and metabolic properties. Transcriptionally, dRIs displayed enrichment for chromatin remodeling, mitochondrial metabolism, proteostasis programs, and an increase in stemness pathways. The isolation and characterization of dRI subclones reveals new avenues for eradicating dRI cells by targeting their distinct metabolic and transcriptional pathways before further evolution renders them fully therapy-resistant. SIGNIFICANCE: Isolation and characterization of subclones from diagnosis samples of patients with B-ALL who relapsed showed that relapse-fated subclones had increased drug tolerance and distinct metabolic and survival transcriptional programs compared with other diagnosis subclones. This study provides strategies to identify and target clinically relevant subclones before further evolution toward relapse.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.